Results 231 to 240 of about 5,003,572 (301)

Treatment of canine hemophilia A via intraosseous delivery of a platelet-specific factor VIII-lentiviral vector. [PDF]

Blood Vessel Thromb Hemost
Rementer CW, Li C, Nichols TC, Cai X, Joo J, Wang X, Kloos M, George N, Chao TY, Xu Y, Poncz M, Ochs HD, Rawlings DJ, Miao CH.   +13 more
europepmc   +1 more source

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy.

Blood
Kashiwakura Y, Nakajima Y, Horinaka K, Lopes TJS, Furuta Y, Yamaguchi Y, Baatartsogt N, Hayakawa M, Katakai Y, Uchiyama S, Nureki O, Nogami K, Ohmori T.   +12 more
europepmc   +1 more source

Molecular etiology of factor VIII deficiency in hemophilia A

Human Mutation, 1995
Hemophilia is a common X-linked coagulation disorder due to deficiency of factor VIII. The factor VIII gene has been cloned in 1984 and a large number of mutations that cause hemophilia A have been identified in the last decade.
Edward Tuddenham, E G Tuddenham
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Studies on the Characterization of Factor VIII and a Co-factor VIII

Thrombosis and Haemostasis, 1974
SummaryFactor VIII occurs in the body in two different forms. In lymph factor VIII is bound to chylomicra. In plasma, factor VIII is bound to a protein.After delipidation of chylomicra we obtained a glycoprotein with a high polysaccharide content and a molecular weight of approx.
M M, Paulssen, H L, Vandenbussche-Scheffers, P B, Spaan, T, de Jong, M C, Planje   +4 more
openaire   +2 more sources

Antihemophilic Factor (Factor VIII)

Annals of Internal Medicine, 1978
Antihemophilic factor (Factor VIII) is an agent in normal plasma that corrects the coagulative defect of classic hemophillia. The plasma of hemophiliacs contains normal amounts of a variant of antihemophilic factor deficient in clot-promoting properties. In contrast, von Willebrand's disease is usually associated with a true deficiency of this protein.
openaire   +2 more sources

Factor VIII inhibitors

Current Opinion in Hematology, 1995
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies.
openaire   +4 more sources

Autoantibodies to factor VIII

Autoimmunity Reviews, 2002
Anti-Factor VIII (FVIII) antibodies represent a unique model to study the relationship between natural autoreactivity (natural antibodies to FVIII of healthy individuals) and disease-associated autoimmunity ('spontaneous' FVIII inhibitors of patients with anti-FVIII autoimmune disease) to a single human protein antigen.
Sébastien, Lacroix-Desmazes, Namita, Misra, Jagadeesh, Bayry, Dipika, Mohanty, Srini V, Kaveri, Michel D, Kazatchkine   +5 more
openaire   +2 more sources